A phase II trial to evaluate the efficacy and safety of GDC-0276 in patients with pain
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs GDC 0276 (Primary)
- Indications Pain
- Focus Therapeutic Use
- 24 Mar 2017 According to a Xenon Pharmaceuticals media release, Genentech plans to initiate Nav1.7 pain program in 2017.
- 18 Mar 2016 New trial record
- 15 Mar 2016 According to Xenon Pharmaceuticals media release, Genentech plans to initiate this phase II trial in 2016.